ondansetron has been researched along with Parapsoriasis in 1 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Parapsoriasis: The term applied to a group of relatively uncommon inflammatory, maculopapular, scaly eruptions of unknown etiology and resistant to conventional treatment. Eruptions are both psoriatic and lichenoid in appearance, but the diseases are distinct from psoriasis, lichen planus, or other recognized dermatoses. Proposed nomenclature divides parapsoriasis into two distinct subgroups, PITYRIASIS LICHENOIDES and parapsoriasis en plaques (small- and large-plaque parapsoriasis).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ondansetron decreased pruritus intensity in prurigo simplex (four patients), asteatotic eczema (two patients), parapsoriasis en plaques, and pruritus of unknown origin (one patient each)." | 7.72 | [Therapy of pruritus associated with skin diseases with the serotonin receptor antagonist ondansetron]. ( Degitz, K; Schuh, T; Zenker, S, 2003) |
| "Ondansetron decreased pruritus intensity in prurigo simplex (four patients), asteatotic eczema (two patients), parapsoriasis en plaques, and pruritus of unknown origin (one patient each)." | 3.72 | [Therapy of pruritus associated with skin diseases with the serotonin receptor antagonist ondansetron]. ( Degitz, K; Schuh, T; Zenker, S, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zenker, S | 1 |
| Schuh, T | 1 |
| Degitz, K | 1 |
1 other study available for ondansetron and Parapsoriasis
| Article | Year |
|---|---|
[Therapy of pruritus associated with skin diseases with the serotonin receptor antagonist ondansetron].
Topics: Administration, Oral; Aged; Aged, 80 and over; Antipruritics; Dermatitis, Atopic; Eczema; Female; Fo | 2003 |